Bayer logo
US MEDICAL AFFAIRS

Publications

Publications

Home/Publications

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated September 16, 2025.

Types of Enhancements Available

Audio Icon
Audio
Infographic Icon
Infographic
Plain language summary icon
Plain Language Summary
Video icon
Video
Digital enhancements icon
Other

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 339    

Filtered results: 31

Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab

Cheon J., et al. Liver Cancer. 2025:446–455.

Cheon J.; Ryoo B.-Y.; Chon H.J.; Kim H.-D.; Ryu M.-H.; Kim ,
READ
EMAIL

Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States

Finn R.S., et al. Journal of Hepatocellular Carcinoma. 2025;12:231-246.

Finn R.S.; Iyer R.; Kalman R.S.; Parikh N.D.; Cabrera R.; B,
READ
EMAIL

Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety

Merle P, et al. Liver Cancer. 2022;12(2):145-155.

Merle P,
READ
EMAIL

Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma - does the sequence matter?

Ng KYY, et al. Asia-Pacific J of clin onc. 2023;19(3):312-319.

Ng KYY,
READ
EMAIL

A prospective phase II study of safety and efficacy of sorafenib followed by Yttrium-90 glass microspheres for patients with advanced or metastatic hepatocellular carcinoma

Kaseb AO, et al. J of hepatocellular carcinoma. 2021;8:1129-1145.

Kaseb AO,
READ
EMAIL

Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.

Singal AG, et al. Cancers. 2023;15(23):5532.

Singal AG,
READ
EMAIL

Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study.

Souza D, et al. Cancers. 2023;15(13):3378.

Souza D,
READ
EMAIL

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

Kim Y.J., et al. Liver Cancer. 2024:391–407.

Kim Y.J.; Merle P.; Finn R.S.; Kudo M.; Klümpen H.-J.; Lim ,
READ
EMAIL

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

Kim HD, et al. Nat Med. 2024;30(3):699-707.

Kim HD,
READ
EMAIL

Prognostic Factors and Predictors of Sorafenib Benefit in Patients With Hepatocellular Carcinoma: Analysis of Two Phase 3 Studies

Bruix J, et al. J Hepatol. 2017;67(5):999-1008.

Bruix J,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2026 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer.

Site last updated 02/2026

Follow Us

Twitter (X) icon Twitter (X) icon
YouTube icon YouTube icon
LinkedIn icon LinkedIn icon
US Medical Affairs QR Code